• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Vaccines, Blood & Biologics

  • Print
  • Share
  • E-mail

Section Contents Menu

Vaccines

Monkey Neurovirulence Safety Testing of GSK Rotarix Vaccine

Date: March 4, 2008
From: Philip Snoy DVM
Director, Division of Veterinary Services/CBER
Subject: Monkey Neurovirulence Safety Testing of GSK Rotarix Vaccine
DATS Log Number 434317, BLA Amendment
Applicant: Glaxosmithkline Biologicals/1617
Product: Rotavirus Vaccine, Live, Oral, Monovalent
Application Number: 125265

I have reviewed the neurovirulence data from two lots of rotavirus vaccine presented in Section 4.2.3.7.7 of the original BLA application submission dated June 2 2007. -----------------------, lot ---------------- and lot ---------------- were each tested in ---------------------------- monkeys ------------------------. All test subjects were inoculated with 0.5 ml of vaccine into the left and right side of the thalamus and then observed for 21 days for neurologic signs. The monkeys were then humanely killed and their brains and spinal cords examined histologically for inflammatory lesions. No excessive neurologic signs were seen clinically, and most of the inflammatory lesions seen in the brain were associated with the inoculation tracks near the thalamus. There was no evidence of viral spread to any areas of the spinal cord.

My evaluation is that there is no indication of neurovirulence in either of the two working seed lots of rotavirus vaccine tested.

 

Contact FDA

(800) 835-4709
(240) 402-8010
Consumer Affairs Branch (CBER)

Division of Communication and Consumer Affairs

Office of Communication, Outreach and Development

Food and Drug Administration

10903 New Hampshire Avenue

Building 71 Room 3103

Silver Spring, MD 20993-0002